Please login to the form below

Not currently logged in
Email:
Password:

MWW's Wadler moves to Zeno

Zeno Group has hired MWW Group's Ame Wadler to serve as managing director health, strategic planning

New York-based Zeno Group has hired MWW Group's Ame Wadler to serve as managing director health, strategic planning, a role that will give her responsibility for expanding Zeno's current healthcare practice.

Wadler served as executive vice president, chief management officer at MWW.  Before joining MWW, she was chief strategic officer and chair of the global healthcare practice at Burson-Marsteller, where she led strategic planning, marketing communications and issues management for ethical and OTC pharmaceuticals, food and nutrition, biotechnology, hospital and lifestyle products.

Earlier in her career, Wadler served as executive vice president on Edelman's healthcare team in New York.

Zeno, which is an Edelman company, counts Schering-Plough, AstraZeneca and Pfizer among its healthcare clients. The company has offices in New York, Washington, DC, Chicago and Los Angeles.

30th September 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics